Murray M et al., 1992: Rat liver microsome study showing that fenbendazole is oxidised by P450 3A and flavin-containing monooxygenase and that its oxidised metabolites inhibit other P450 reactions. The authors investigate whether this inhibition plays a role in benzimidazole potentiation.
In untreated rat liver, the sulfoxide and (4'-hydroxyphenyl)thio metabolites of fenbendazole were relatively potent inhibitors of P450-mediated androstenedione 16 alpha-, 16 beta-, and 6 beta-hydroxylation
Murray M et al., 1992: Rat liver microsome study showing that fenbendazole is oxidised by P450 3A and flavin-containing monooxygenase and that its oxidised metabolites inhibit other P450 reactions. The authors investigate whether this inhibition plays a role in benzimidazole potentiation. In vitro study (rat liver microsomes); no patients; Australia (University of Sydney, Westmead Hospital); fenbendazole and metabolites at micromolar concentrations; induction by phenobarbital or dexamethasone in vivo before microsomes were prepared. Funder: Australian national research support. Declared conflicts: none recorded. Comparator: untreated microsomes and isoform-selective inhibitors. Relevant to C5 because it shows the interaction runs both ways: the drug is a P450 substrate and its metabolites inhibit P450. Study type: lab.
